These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

720 related items for PubMed ID: 18232728

  • 21. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
    Hwang RF, Yokoi K, Bucana CD, Tsan R, Killion JJ, Evans DB, Fidler IJ.
    Clin Cancer Res; 2003 Dec 15; 9(17):6534-44. PubMed ID: 14695158
    [Abstract] [Full Text] [Related]

  • 22. Assessment of antiangiogenic effect of imatinib mesylate on vestibular schwannoma tumors using in vivo corneal angiogenesis assay.
    Yener U, Avsar T, Akgün E, Şeker A, Bayri Y, Kılıç T.
    J Neurosurg; 2012 Oct 15; 117(4):697-704. PubMed ID: 22900848
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
    Dong Y, Jia L, Wang X, Tan X, Xu J, Deng Z, Jiang T, Rainov NG, Li B, Ren H.
    Int J Oncol; 2011 Feb 15; 38(2):555-69. PubMed ID: 21152856
    [Abstract] [Full Text] [Related]

  • 27. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571.
    McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, Fidler IJ, Bar-Eli M.
    Clin Cancer Res; 2002 Nov 15; 8(11):3584-91. PubMed ID: 12429650
    [Abstract] [Full Text] [Related]

  • 28. Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor.
    Rosenberg A, Mathew P.
    Expert Opin Investig Drugs; 2013 Jun 15; 22(6):787-94. PubMed ID: 23540855
    [Abstract] [Full Text] [Related]

  • 29. The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer.
    Roussidis AE, Theocharis AD, Tzanakakis GN, Karamanos NK.
    Curr Med Chem; 2007 Jun 15; 14(7):735-43. PubMed ID: 17346159
    [Abstract] [Full Text] [Related]

  • 30. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.
    Hasumi Y, Kłosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C.
    Int J Cancer; 2007 Dec 15; 121(12):2606-14. PubMed ID: 17691110
    [Abstract] [Full Text] [Related]

  • 31. Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B.
    Falcon BL, Pietras K, Chou J, Chen D, Sennino B, Hanahan D, McDonald DM.
    Am J Pathol; 2011 Jun 15; 178(6):2920-30. PubMed ID: 21641409
    [Abstract] [Full Text] [Related]

  • 32. Pharmacology of imatinib (STI571).
    Buchdunger E, O'Reilly T, Wood J.
    Eur J Cancer; 2002 Sep 15; 38 Suppl 5():S28-36. PubMed ID: 12528770
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
    Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, Hirte H, Cresta S, Koslin DB, Corless CL, Dirnhofer S, van Oosterom AT, Nikolova Z, Dimitrijevic S, Fletcher JA.
    J Clin Oncol; 2006 Mar 01; 24(7):1195-203. PubMed ID: 16505440
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function.
    Semela D, Das A, Langer D, Kang N, Leof E, Shah V.
    Gastroenterology; 2008 Aug 01; 135(2):671-9. PubMed ID: 18570897
    [Abstract] [Full Text] [Related]

  • 38. Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor.
    Abouantoun TJ, MacDonald TJ.
    Mol Cancer Ther; 2009 May 01; 8(5):1137-47. PubMed ID: 19417143
    [Abstract] [Full Text] [Related]

  • 39. Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.
    Calipel A, Landreville S, De La Fouchardière A, Mascarelli F, Rivoire M, Penel N, Mouriaux F.
    Clin Exp Metastasis; 2014 Jun 01; 31(5):553-64. PubMed ID: 24652072
    [Abstract] [Full Text] [Related]

  • 40. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
    Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G, O'Brien-Jenkins A, Randall TC, Rubin SC, Coukos G.
    Cancer Res; 2003 Jun 15; 63(12):3403-12. PubMed ID: 12810677
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.